The Critical Lean Mass Question The most reassuring finding for body recomposition purposes concerns lean mass preservation
This is achieved through its twofold mechanism of increased insulin secretion and glucagon suppression
Hormone therapy, when used before surgery or radiation therapy as an adjuvant therapy, can decrease tumor size and lower the risk for tumor recurrence
Notably, various exendin-4-based GLP-1RAs (Exenatide: 39 aa and Lixisenatide: 44 aa), and GLP-1-based GLP-1RAs (Dulaglutide: 31 aa, Liraglutide: 31 aa, Semaglutide: 31 aa, Tirzepatide: 39 aa, and Albiglutide: 60 aa) have been developed and approved by the FDA between 2005 and 2022 for the management of T2DM (Liu, 2024)
After you receive your GLP-1 medication, you can expect monthly check-ins by Fella and Hims healthcare professionals
Vinken et al